Geron could get lift from Sanofi's myelofibrosis troubles

|About: Geron Corporation (GERN)|By:, SA News Editor

Shares of Geron (GERN) are up 1.5% before the bell.

Although premarket volume is low, the stock could get a boost during the regular session from news that Sanofi has suspended studies of fedratinib.

For more on myelofibrosis, see here.